Solventum
SOLV
$86.67
+0.32%
Solventum Corporation is the healthcare business spun out of 3M in spring 2024, operating in the medical instruments and supplies industry across three remaining segments: MedSurg (roughly 64% of revenue, including advanced wound care and wound prevention), Dental Solutions (restorative composites and orthodontia, ~18%), and Health Information Systems (primarily revenue cycle management, ~18%), following the divestiture of the smaller purification and filtration unit. The company is a scaled, carve-out medtech platform with roughly 20,000 employees and deep incumbent positions in hospital wound-care protocols and dental consumables, giving it a defensive, procedure-driven revenue base rather than a high-growth technology profile. The current investor debate centers on post-spin execution: whether management can reignite organic growth that has recently turned slightly negative, whether the portfolio pruning (purification and filtration sale) and bolt-on M&A can lift the growth algorithm, and how quickly the company can deleverage a balance sheet inherited with meaningful spin-related debt. Sentiment has warmed materially through 2026, with several broker upgrades (KeyBanc to Overweight, Mizuho to Outperform, BTIG to Buy) reflecting growing confidence in the standalone margin story and capital allocation, even as the top line remains the key point of contention.…
SOLV
Solventum
$86.67
Investment Opinion: Should I buy SOLV Today?
Rating: Hold with a constructive bias. The core thesis is that SOLV is a cheap, defensive, cash-generative-once-normalized medtech carve-out (1.66x sales, 7.04x EV/EBITDA) whose upside depends entirely on turning organic growth positive, and the analyst consensus of 'buy' with a mean rating of 2.2 and an average target of $94.69 (+10.3%) supports a patient stance rather than an aggressive one.\n\nSupporting evidence is mixed but leans favorable on valuation: the 1.66x PS and 7.04x EV/EBITDA sit well below the 3-5x and 12-15x medtech benchmarks, the 53.5% gross margin and 26.2% operating margin are competitive, and trailing ROE of 30.8% shows the franchise is profitable. However, revenue growth of -3.71% year-over-year and trailing free cash flow of -$10 million are the counterweights, and the forward PE of 11.84x versus trailing 8.86x confirms earnings normalize downward once the one-time Q3 2025 gain is removed. The +10.3% implied upside to the $94.69 average target is modest for the risk taken.\n\nThe biggest risks that could invalidate the thesis are a failure to turn organic growth positive, continued negative free cash flow that stalls deleveraging, and multiple compression if the market decides the discount is structural. This Hold would upgrade to Buy if organic growth turns positive and FCF inflects above $200 million annually, or if the stock pulls back toward the $75-$78 support zone; it would downgrade to Sell if revenue declines accelerate beyond -5% or if the stock breaks below $82 on rising volume. On balance the stock is fairly valued to modestly undervalued relative to its own history and peers, but not yet a compelling buy until the top line stabilizes.
Sign up to view all
SOLV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Solventum's 12-month outlook, with a consensus price target around $94.69 and implied upside of +9.3% versus the current price.
Average Target
$94.69
0 analysts
Implied Upside
+9.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$71 - $113
Analyst target range
Coverage is solid with 13 analysts, and the consensus is bullish: the recommendation is "buy" with a mean rating of 2.2, and the average target price of $94.69 implies roughly +10.3% upside from the current $85.81. The consensus leans constructive but not euphoric, consistent with a stock that has already rallied 20% over the past year and now trades near the upper end of its range; the average target sits almost exactly at the 52-week high of $94.16, suggesting analysts see limited near-term multiple expansion beyond a retest of the highs. Institutional ratings show a clear upgrade cycle through late 2025 and early 2026: KeyBanc moved to Overweight from Sector Weight (January 2026), Mizuho to Outperform from Neutral (January 2026), and BTIG to Buy from Neutral (December 2025), while Wells Fargo and UBS remain at Equal Weight/Neutral, indicating the bull case is gaining traction but is not unanimous. The target range of $71.00 to $113.00 is wide, spanning -17.3% downside to +31.7% upside from the current price, which signals meaningful disagreement about the growth and margin trajectory. The high target of $113 likely assumes successful portfolio transformation, positive organic growth, and multiple re-rating toward medtech peers, while the low target of $71 prices in continued revenue erosion, margin compression from spin-related costs, and a stalled deleveraging path; the wide spread argues for position sizing discipline and attention to quarterly organic growth as the key catalyst.
Drowning in data?
Find the real signal!
Bulls vs Bears: SOLV Investment Factors
The bear case currently has slightly stronger near-term evidence because the single most important variable — organic growth — is still negative at -3.71% year-over-year, and free cash flow of -$10 million undermines the deleveraging narrative that underpins the bull thesis. The bull case rests on valuation (1.66x sales, 7.04x EV/EBITDA versus 3-5x and 12-15x peer norms), a broadening analyst upgrade cycle, and a defensive 53.5% gross margin franchise, all of which are real but require a growth inflection to crystallize. The most important tension in the debate is whether management can turn organic growth positive; if it does, the multiple discount closes and the $94.69 average target (and $113 high) becomes achievable, but if revenue keeps eroding, the low target of $71 (-17.3%) becomes the gravity point. Momentum and sentiment have clearly warmed — the stock is up 21.75% over six months and outperforming SPY by 14.27 points — but that rally has priced in much of the easy margin story, leaving the top line as the swing factor.
Bullish
- Deep valuation discount to medtech peers: SOLV trades at 1.66x sales and 7.04x EV/EBITDA versus the 3-5x sales and 12-15x EBITDA typical of scaled medical device franchises. Even a partial re-rating toward peer multiples would imply substantial upside, and the stock sits near the bottom of its own historical PS range after compressing from 6.90x.
- Analyst upgrade cycle gaining traction: Consensus is 'buy' with a mean rating of 2.2 across 13 analysts and an average target of $94.69, implying +10.3% upside from $85.81. KeyBanc (Overweight), Mizuho (Outperform) and BTIG (Buy) all upgraded between December 2025 and January 2026, with the high target of $113 implying +31.7%.
- Strong relative strength and low-beta profile: SOLV has outperformed the S&P 500 by 14.27 points over six months and 4.58 points over one year, with a beta of just 0.703. The stock is up 21.75% over six months and sits at 91.1% of its 52-week range, confirming genuine momentum leadership rather than beta-driven drift.
- Solid core profitability and margins: Trailing gross margin of 53.5% and operating margin of 26.2% demonstrate real pricing power, while trailing ROE of 30.8% and net margin of 18.69% show the core franchise is solidly profitable once one-time spin and divestiture items are stripped out. Interest coverage of 32.9x confirms debt is comfortably serviced.
Bearish
- Organic revenue is shrinking: Q4 2025 revenue of $1.998 billion fell 3.71% year-over-year, and the sequential erosion from the Q2 peak of $2.161 billion to $1.998 billion shows organic growth remains elusive. Consensus forward revenue of ~$9.62 billion implies only modest stabilization, not a reacceleration.
- Negative free cash flow constrains the story: Trailing free cash flow is -$10 million, with Q4 2025 FCF of just $32 million against $63 million of capex and $95 million of operating cash flow. A cash flow-to-debt ratio of 0.019 means deleveraging and bolt-on M&A must be funded largely from asset sales rather than organic cash generation.
- Leverage inherited from the spin: Debt-to-equity stands at 0.997 with a current ratio of only 1.23. The balance sheet was loaded with spin-related debt, and with thin FCF the deleveraging path is slow, keeping a structural overhang on the equity and limiting capital return flexibility (payout ratio of 0%).
- Earnings quality is noisy and distorted: The trailing PE of 8.86x is flattered by a one-time $1.27 billion Q3 2025 gain from the purification and filtration divestiture, while the forward PE of 11.84x is higher, implying earnings normalize downward. Quarterly net margins swung from 6.62% to 60.4% to 3.15%, making the earnings base unreliable.
SOLV Technical Analysis
SOLV is in a sustained, powerful uptrend: the stock is up 20.11% over the past year and 21.75% over six months, and at $85.81 it sits at roughly 91.1% of its 52-week range of $62.38 to $94.16, just 8.9% below the high. That positioning near the top of the range signals momentum leadership rather than a value opportunity, though it also means the stock is extended and vulnerable to profit-taking. Notably, the stock has outperformed the S&P 500 by 4.58 percentage points over one year and a striking 14.27 points over six months, confirming genuine relative strength rather than beta-driven drift. Short-term momentum, however, has decelerated: the stock is down 3.40% over the past month versus a +1.22% gain for SPY, a -4.62 point relative-strength gap, while the three-month change remains a positive 5.53% (2.84 points ahead of SPY). This one-month softness against a strong one-year trend looks more like a consolidation/pause after the July-August run from the high-$70s to the low-$90s than a trend reversal, particularly since the pullback has been orderly and the stock is still up 8.59% year-to-date despite SPY's 11.93% YTD gain (a -3.34 point YTD relative-strength gap). Key levels are well defined: support sits at the 52-week low of $62.38, with intermediate support around the $82-$83 area where the stock consolidated in August, while resistance is the 52-week high of $94.16, last touched in early September. A breakout above $94.16 would confirm the multi-month uptrend and likely open a new leg higher, whereas a breakdown below $82 would signal a deeper mean-reversion move toward the $75-$78 zone; the beta of 0.703 means the stock is roughly 30% less volatile than the market, which supports larger position sizing for a given risk budget but also implies the stock will lag in sharp risk-on rallies. The maximum drawdown of -27.46% over the trailing period underscores that even this low-beta name has had meaningful air pockets, and the elevated short ratio of 5.55 days-to-cover suggests some persistent bearish positioning that could fuel squeezes on upside surprises.
Beta
0.70
0.70x market volatility
Max Drawdown
-27.5%
Largest decline past year
52-Week Range
$62-$94
Price range past year
Annual Return
+18.9%
Cumulative gain past year
| Period | SOLV Return | S&P 500 |
|---|---|---|
| 1m | -2.4% | -0.1% |
| 3m | +12.2% | +4.7% |
| 6m | +26.5% | +8.3% |
| 1y | +18.9% | +15.2% |
| ytd | +9.7% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SOLV Fundamental Analysis
Revenue is stagnating to slightly declining: the most recent quarter (Q4 2025) posted $1.998 billion, down 3.71% year-over-year, continuing a pattern of roughly flat-to-down prints across 2025 ($2.070B in Q1, $2.161B in Q2, $2.096B in Q3, $1.998B in Q4) versus $2.075B in Q4 2024. The sequential erosion from the Q2 peak of $2.161 billion to $1.998 billion in Q4 is a warning sign that organic growth remains elusive, and with product revenue of $1.49 billion in the disclosed segment, the portfolio is heavily concentrated in slower-growth consumables. For the investment case, the growth trend is the central risk: a spin-off with negative organic growth must rely on margin expansion, portfolio actions, and capital returns to create value, and consensus revenue of ~$9.62 billion for the forward period implies only modest stabilization rather than a reacceleration. Profitability is improving but noisy: Q4 2025 net income was $63 million (a 3.15% net margin) on a 49.3% gross margin, and the trailing gross margin of 53.5% with a 26.2% operating margin reflects a business with strong underlying pricing power but heavy spin-related and restructuring costs. The quarterly net margin path has been erratic ($6.62% in Q1 2025, 4.16% in Q2, a distorted 60.4% in Q3 due to a large one-time gain, and 3.15% in Q4), so the cleaner read is the trailing net margin of 18.69% and ROE of 30.8%, which indicate the core franchise is solidly profitable once one-time items are stripped out. Balance sheet and cash flow are the weak spot: debt-to-equity stands at 0.997, the current ratio is 1.23, and trailing free cash flow is -$10 million, with Q4 2025 FCF of just $32 million against $63 million of capex and only $95 million of operating cash flow. The cash flow-to-debt ratio of 0.019 and interest coverage of 32.9x (on trailing operating income) show the company can service its debt, but the thin FCF generation means deleveraging and M&A must be funded largely from operations and asset sales rather than organic cash generation, which is a genuine constraint on the turnaround narrative.
Quarterly Revenue
$2.0B
2025-12
Revenue YoY Growth
-3.7%
YoY Comparison
Gross Margin
49.3%
Latest Quarter
Free Cash Flow
$-10000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SOLV Overvalued?
Because net income is positive ($63 million in Q4 2025, trailing EPS of $0.11), the PE ratio is the appropriate primary metric, and the picture is bifurcated: the trailing PE of 8.86x is remarkably low, while the forward PE of 11.84x is higher, implying the market expects earnings to normalize downward from a trailing base distorted by one-time gains (the Q3 2025 $1.27 billion net income from the purification and filtration divestiture). The gap between trailing and forward PE therefore does not signal growth optimism but rather the unwind of a non-recurring earnings boost, and the PEG ratio of 0.04 is essentially meaningless given the distorted earnings base. On peer comparison, SOLV trades at a PS of 1.66x and EV/Sales of 2.39x against a healthcare supplies sector where quality medtech names typically command 3-5x sales, and its EV/EBITDA of 7.04x is well below the 12-15x range typical for scaled medical device franchises, a discount that reflects the negative organic growth, spin-off overhang, and thin free cash flow. The premium/discount question is really about whether the market is correctly pricing a low-growth, deleveraging story: the 53.5% gross margin and 26.2% operating margin are competitive, but the 1.66x sales multiple implies investors are skeptical of the growth trajectory. Historically, SOLV's own PE band has been extremely wide and distorted (54.7x at Q4 2025, 2.51x at Q3 2025, 36.7x at Q2 2025, 24.1x at Q1 2025), while its PS ratio has compressed from 6.90x at Q4 2025 to the current 1.66x, placing the stock near the bottom of its own historical sales-multiple range. That compression suggests either a value opportunity if margins and cash flow inflect, or a market judgment that the standalone entity deserves a structurally lower multiple until growth turns positive.
PE
8.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the combination of negative organic growth and weak cash generation. Q4 2025 revenue of $1.998 billion fell 3.71% year-over-year and has declined sequentially from the $2.161 billion Q2 peak, while trailing free cash flow is -$10 million and Q4 FCF was only $32 million against $63 million of capex. Debt-to-equity of 0.997 and a current ratio of 1.23 leave limited balance-sheet cushion, and a cash flow-to-debt ratio of 0.019 means the company depends on asset-sale proceeds (such as the purification and filtration divestiture) rather than operations to deleverage. Revenue is also concentrated: MedSurg is roughly 64% of the total, so any pressure on wound-care reimbursement or hospital procedure volumes hits the core directly.\n\nMarket and competitive risks stem from the valuation debate and the spin-off overhang. SOLV trades at 1.66x sales and 7.04x EV/EBITDA, a discount to the 3-5x and 12-15x typical of scaled medtech, but that discount can persist or widen if growth stays negative — the stock's own PS has already compressed from 6.90x. With a beta of 0.703 the name is roughly 30% less volatile than the market, which cushions drawdowns but also means it will lag in sharp risk-on rotations. The wide analyst target range of $71 to $113 (-17.3% to +31.7%) signals genuine disagreement, and the recent one-month underperformance of -4.62 points versus SPY, alongside a 5.55-day short ratio, shows sentiment can turn quickly if quarterly organic growth disappoints.\n\nThe worst-case scenario is a renewed leg of revenue erosion combined with a stalled deleveraging path: organic growth stays negative, spin-related costs keep margins noisy, and the market re-rates the stock toward the low end of its range. In that chain, the stock could retest the 52-week low of $62.38, which is roughly -27.3% from the current $85.81, and the analyst low target of $71 implies about -17.3% downside. The trailing max drawdown of -27.46% confirms this magnitude is realistic rather than theoretical, so an investor should size positions assuming a plausible 17-27% loss in an adverse outcome.
FAQ
The most severe risk is financial: revenue fell 3.71% year-over-year in Q4 2025 and trailing free cash flow is -$10 million, which undermines the deleveraging story given debt-to-equity of 0.997. Second is valuation/technical risk: the stock is extended at 91.1% of its 52-week range and has underperformed SPY by 4.62 points over the past month, with a 5.55-day short ratio signaling persistent bearish positioning. Third is company-specific execution risk around spin-related costs, which keep quarterly net margins erratic (from 3.15% to 60.4%). Fourth is concentration risk, with MedSurg at roughly 64% of revenue exposed to hospital wound-care reimbursement and procedure volumes. Ranked by severity, the growth and cash flow risks outweigh the valuation and technical risks.
The base case (50% probability) targets $88-$95, aligned with the analyst average of $94.69 and the 52-week high of $94.16, assuming revenue stabilizes near the ~$9.62 billion consensus and free cash flow turns modestly positive. The bull case (25% probability) targets $105-$113, aligned with the analyst high target, assuming organic growth turns positive and the multiple re-rates toward medtech peers. The bear case (25% probability) targets $62-$71, aligned with the analyst low target and the 52-week low, assuming revenue erosion continues and deleveraging stalls. The base case is most likely, and its key assumption is that margins hold near 53.5% gross and 26.2% operating while spin costs roll off.
SOLV looks undervalued on relative metrics. It trades at 1.66x sales and 7.04x EV/EBITDA versus the 3-5x sales and 12-15x EBITDA typical of scaled medtech franchises, and its PS has compressed from 6.90x to near the bottom of its own historical range. The trailing PE of 8.86x is flattered by a one-time $1.27 billion Q3 2025 divestiture gain, while the forward PE of 11.84x is higher, implying earnings normalize downward. The market is therefore pricing in skepticism about the growth trajectory and the spin-off overhang rather than paying a premium. If organic growth turns positive, the discount could close meaningfully; if it stays negative, the low multiple may be deserved.
From a risk/reward perspective SOLV is a reasonable but not compelling buy at $85.81. The analyst consensus is 'buy' with a mean rating of 2.2 and an average target of $94.69, implying +10.3% upside, while the high target of $113 implies +31.7%. The valuation is cheap at 1.66x sales and 7.04x EV/EBITDA versus medtech peers, and the 53.5% gross margin and 30.8% ROE show a solid franchise. However, the biggest downside risk is a retest of the $71 low target (-17.3%) or the $62.38 52-week low (-27.3%) if organic growth stays negative. It is a good buy for patient, value-oriented investors who can tolerate a 17-27% drawdown and wait for a growth inflection, but less attractive for momentum or short-term traders given the -4.62 point one-month relative-strength gap.
SOLV is better suited to a long-term holding period of at least 12-18 months. It is a post-spin carve-out still normalizing its cost structure, with negative trailing free cash flow and a deleveraging path that will take multiple quarters to play out, so the value-unlock thesis needs time. The beta of 0.703 means lower volatility and smaller drawdowns, which supports patient position sizing, but the -27.46% max drawdown and 5.55-day short ratio show short-term air pockets are real. With no dividend (payout ratio 0%), there is no income incentive to hold short-term. Short-term traders could trade the $82-$94.16 range, but the fundamental case is a multi-quarter recovery story best held through the next several earnings cycles.